Loading…
Reported covered position: SPA, Sen Stabenow(05-07)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · 4A
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · Q4
Source: Senate LDA
| AMNEAL PHARMACEUTICALS |
| 18 |
| 2013–2017 |
| MIRACA LIFE SCIENCES | 17 | 2012–2016 |
| QUALITY DIABETES CARE COALITION | 14 | 2010–2013 |
| EXELA HOLDINGS, LLC | 8 | 2014–2016 |
| SURGICAL CARE AFFILIATES | 8 | 2009–2010 |
| ZYDUS PHARMACEUTICALS (USA) INC. | 8 | 2014–2016 |
| HEALTH CARE NAVIGATORS, LLC | 7 | 2011–2012 |
| NATIONAL PARTNERSHIP FOR WOMEN AND FAMILIES | 7 | 2009–2010 |
| NORWALK HOSPITAL | 6 | 2009–2010 |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 5 | 2009–2010 |
| NEUROSCIENCE CENTERS OF FLORIDA FOUNDATION, INC. | 4 | 2012 |
| REVIVAL HOME HEALTH CARE | 3 | 2011 |
| VILLAGE HEALTH | 2 | 2011 |
| HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 1 | 2010 |
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
Prescription Drug Price Transparency Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act; H.R. 1628, the American Health Care Act of 2017, Senate proposals to repeal the Affordable Care Act.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R.1606-DOC Access Act; H.R.1628-The American Health Care Act of 2017;Senate proposals to repeal the Affordable Care Act;The Bipartisan Health Care Stabilization Act of 2017;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
American Health Care Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act; H.R. 1628, the American Health Care Act of 2017, Senate proposals to repeal the Affordable Care Act.
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
American Health Care Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage;tax issues related to ACA repeal.H.R. 1628-American Health Care Act of 2017, provisions related to the business of dental benefits;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
American Health Care Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
American Health Care Act of 2017
Client: ASSOCIATION FOR BEHAVIORAL HEALTHCARE · Firm: BROWN RUDNICK LLP
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
American Health Care Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R.1606-DOC Access Act; H.R.1628-The American Health Care Act of 2017;Senate proposals to repeal the Affordable Care Act;The Bipartisan Health Care Stabilization Act of 2017;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
American Health Care Act of 2017
Client: ASSOCIATION FOR BEHAVIORAL HEALTHCARE · Firm: BROWN RUDNICK LLP
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Senate proposals to repeal the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
American Health Care Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
American Health Care Act of 2017
Client: ASSOCIATION FOR BEHAVIORAL HEALTHCARE · Firm: BROWN RUDNICK LLP
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Senate proposals to repeal the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
H.R. 2051 - The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2051 - The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
Patients' Access to Treatments Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests.
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House and Senate proposal for a regulatory framework for in-vitro clinical tests.
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
Protecting Families and Small Businesses Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage;tax issues related to ACA repeal.H.R. 1628-American Health Care Act of 2017, provisions related to the business of dental benefits;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
Protecting Families and Small Businesses Act of 2017
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R.1606-DOC Access Act; H.R.1628-The American Health Care Act of 2017;Senate proposals to repeal the Affordable Care Act;The Bipartisan Health Care Stabilization Act of 2017;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
Lower Drug Costs through Competition Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
Lower Drug Costs through Competition Act
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
Lower Drug Costs through Competition Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
HR 749 - The Lower Drug Costs Through Competition Act
Lower Drug Costs through Competition Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes.
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests.
Protecting Access to Diabetes Supplies Act of 2017
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House and Senate proposal for a regulatory framework for in-vitro clinical tests.
Increasing Competition in Pharmaceuticals Act
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Affordable and Safe Prescription Drug Importation Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
S.469-The Affordable and Safe Prescription Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
S.469-The Affordable and Safe Prescription Drug Importation Act.
Affordable and Safe Prescription Drug Importation Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
S.469-The Affordable and Safe Prescription Drug Importation Act
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
Improving Access To Affordable Prescription Drugs Act
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: PRIME THERAPEUTICS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2051 - The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Protecting Our Infants Act of 2015
Client: ASSOCIATION FOR BEHAVIORAL HEALTHCARE · Firm: BROWN RUDNICK LLP
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953, and H.R. 1462
Access to Quality Diabetes Education Act of 2015
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
Access to Quality Diabetes Education Act of 2015
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 34 - Century Cures Act
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; Innovations for Healthier Americans
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act; HR 34-21st Century Cures Act
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 34 - Century Cures Act
HRC: S.3056-CREATES; HR 34 - 21st Century Cures Act.
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act; HR 34-21st Century Cures Act
Aligning Children's Dental Coverage Act
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, Aligning Children's Dental Coverage Act" ; S. 3244, Aligning Childrens Dental Coverage Act
Issues relating to inter parte review challenges.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · fourth_quarter · 4T
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage;tax issues related to ACA repeal.H.R. 1628-American Health Care Act of 2017, provisions related to the business of dental benefits;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R.1606-DOC Access Act; H.R.1628-The American Health Care Act of 2017;Senate proposals to repeal the Affordable Care Act;The Bipartisan Health Care Stabilization Act of 2017;H.R.4620-Protecting Families and Small Businesses Act of 2017 as related to the Fee on Health Insurance Providers on dental plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2017 · fourth_quarter · 4T
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Senate proposals to repeal the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · fourth_quarter · 4T
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests.
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017;S. 1914 - Protecting Access to Diabetes Supplies Act of 2017;Yet to be introduced House and Senate proposal for a regulatory framework for in-vitro clinical tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Senate proposals to repeal the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act; H.R. 1628, the American Health Care Act of 2017, Senate proposals to repeal the Affordable Care Act.
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; yet to be introduced Senate proposal on Medicare competitive bidding related to diabetes testing supplies; Yet to be introduced House proposal for a regulatory framework for in-vitro clinical tests; Yet to be introduced Senate proposal for a regulatory framework for in-vitro clinical tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
S.469-The Affordable and Safe Prescription Drug Importation Act.
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · third_quarter · Q3
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · third_quarter · Q3
Issues relating to inter parte review challenges.
HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Issues relating to inter parte review challenges.
H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; H.R. 1628, the American Health Care Act of 2017, provisions related to the business of dental benefits. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to the business of dental benefits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2017 · second_quarter · 2A
Issues and policies relating to mental health and substance use disorder parity. H.R. 1628, the American Health Care Act of 2017, provisions related to Medicaid and mental health and substance use. Yet to be introduced Senate legislation related to repeal of the Affordable Care Act, provisions related to Medicaid and mental health and substance use.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2017 · second_quarter · Q2
Issues and policies relating to mental health and substance use disorder parity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
H.R. 2051 - The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · second_quarter · Q2
S.469-The Affordable and Safe Prescription Drug Importation Act
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Issues and policies relating to mental health and substance use disorder parity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
HR 749 - The Lower Drug Costs Through Competition Act; H.R. 2051 - The FAST Generics Act; S. 297-Increasing Competition in Pharmaceuticals Act; S.469-The Affordable and Safe Prescription Drug Importation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2017 · first_quarter · Q1
HR 749 - The Lower Drug Costs Through Competition Act
Issues relating to reauthorization of the Generic Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
S.469-The Affordable and Safe Prescription Drug Importation Act
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Yet to be introduced House proposal to have the FDA regulate laboratory developed tests; Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests; Yet to be introduced House proposal on Medicare competitive bidding proposal related to diabetes supplies; Yet to be introduced Senate proposal on Medicare competitive bidding proposal related to diabetes supplies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2017 · first_quarter · Q1
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage; issues and policies related to preserving Medicaid dental coverage; issues and policies related to ensuring a competitive market for dental benefits and allowing purchase of dental benefits as part of a medical policy or on a standalone basis; issues and policies related to ensuring continuity of dental coverage; funding for the Childrens Health Insurance Program; H.R. 1606 - DOC Access Act
issues and policies related to ensuring tax incentives for employers and individuals to purchase dental coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, Aligning Children's Dental Coverage Act" ; S. 3244, Aligning Childrens Dental Coverage Act
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2016 · fourth_quarter · 4A
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 34 - Century Cures Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act; HR 34-21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
HRC: S.3056-CREATES; HR 34 - 21st Century Cures Act.
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2016 · fourth_quarter · Q4
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · Q3
HRC: S.3056-CREATES
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · 3A
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies; H.R.1726 - Access to Quality Diabetes Education Act of 2015
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, Aligning Children's Dental Coverage Act" ; S. 3244, Aligning Childrens Dental Coverage Act
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2016 · third_quarter · Q3
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · third_quarter · Q3
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · second_quarter · Q2
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
S.131 - The FAIR Generics Act; S. 2615 - Increasing Competition in Pharmaceutical Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; S.3056-The CREATES Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Federal policy relating to pharmaceutical pricing and FDA application review protocols
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; H.R. 6 "21st Century Cures Act"; Not yet introduced Senate proposal on Medicare competitive bidding related to diabetes supplies
H.R.6-21st Century Cures Act Yet to be introduced House proposal to have the FDA regulate laboratory developed tests Yet to be introduced Senate proposal to have the FDA regulate laboratory developed tests H.R. 771-Protecting Access to Diabetes Supplies Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · second_quarter · Q2
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit; H.R. 3463, "Aligning Children's Dental Coverage Act", yet to be introduced Senate companion bill to H.R. 3463
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Issues relating to GDUFA implementation and pharmaceutical pricing; S.131 - The FAIR Generics Act; S. 2615 - Increasing Competition in Pharmaceutical Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to pharmaceutical pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to pharmaceutical pricing and FDA application review protocols
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; Innovations for Healthier Americans
Federal policy relating to abuse deterrent drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Federal policy relating to prescription drug abuse and preferred pharmacy networks
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953, and H.R. 1462
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2016 · first_quarter · Q1
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2016 · first_quarter · 1T
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223; issues relating to reform of the mental health system; and S. 524, H.R. 953, and H.R. 1462
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Federal policy relating to pricing of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Federal policy relating to ANDA review
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
H.R.3762 - Restoring Americans' Healthcare Freedom Reconciliation Act of 2015 relating to pharmaceutical importation; H.R. 2029 - FY 2016 Consolidated Appropriations Act and the Protecting Americans from Tax Hikes Act of 2015
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
H.R. 2841-Fair Access to Safe and Timely (FAST) Generics Act; Innovations for Healthier Americans
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Medicare Part D policy relating to the Medication Therapy Management program, prescription drug abuse and preferred pharmacy networks.
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2015 · fourth_quarter · Q4
Public Law No: 114-74 relating to generic drug Medicaid inflation rebate
Federal policy relating to federal procurement country of origin requirements for pharmaceuticals
H.R. 6 - The 21st Century Cures Act; Senate Innovations for Healthier Americans; Federal policy relating to GDUFA implementation and pricing of pharmaceuticals
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · third_quarter · 3A
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Issues relating to generic drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Issues relating to ANDA review and approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2015 · third_quarter · Q3
H.R.2841 - FAST Generics Act of 2015
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to abuse deterrent drug development
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2015 · third_quarter · Q3
Implementation of the Biologics Price Competition and Innovation Act (BPCIA); CMS Proposed Rule {CMS-1631-P} RIN 0938-AS40 - Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2016
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program.
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2015 · third_quarter · 3T
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
CMS Proposed Rule {CMS-1631-P} RIN 0938-AS40 - Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2016
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2015 · third_quarter · Q3
H.R.6 - 21st Century Cures Act; ; H.R.2841 - FAST Generics Act of 2015; CMS Proposed Rule {CMS-1631-P} RIN 0938-AS40 - Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2016
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Policies related to diagnostic laboratory testing; H.R. 771 Protecting Access to Diabetes Supplies; S. 1101 Medical Electronic Data Technology Enhancement for consumers Health Act; H.R. 6 "21st Century Cures Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Issues and policies relating to community behavioral health centers; issues and policies relating to behavioral healthcare; issues and policies relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Calculation of the advanced premium tax credit as related to the pediatric dental benefit.
Implementation of Affordable Care Act and related regulations related to the pediatric dental benefit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Proposals related to anatomic pathology and the in-office ancillary services exception to the Ethics in Patient Referrals Act.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Issues relating to generic drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Issues relating to ANDA review and approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
H.R.6 - 21st Century Cures Act; H.R.2841 - FAST Generics Act of 2015
Issues relating to abuse deterrent drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program.
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
APOTEX CORPORATION via BROWN RUDNICK LLP
2015 · second_quarter · Q2
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
H.R.6 - 21st Century Cures Act; ; H.R.2841 - FAST Generics Act of 2015; Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR BEHAVIORAL HEALTHCARE via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Issues relating to community behavioral health centers; issues relating to behavioral healthcare; issues relating to access to community-based addiction treatment services; implementation of Public Law 113-93 Section 223.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2015 · first_quarter · 1A
Issues relating to diagnostic laboratory testing; H.R. 771, "Protecting Access to Diabetes Supplies;" issues related to regulation of medical electronic data technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Issues relating to diagnostic laboratory testing; H.R. 771, "Protecting Access to Diabetes Supplies;" issues related to regulation of medical electronic data technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2015 · first_quarter · Q1
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
MIRACA LIFE SCIENCES via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Issues related to anatomic pathology and the "in-office ancillary" services exception to the Ethics in Patient Referrals Act; Policies impacting Medicare reimbursement for anatomic pathology services.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Issues relating to generic drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Issues relating to ANDA review and approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2015 · first_quarter · Q1
House 21st Century Cures Act Discussion Draft relating to restricted access drug programs
Issues relating to abuse deterrent drug development
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to ANDA review and approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2015 · first_quarter · Q1
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program. Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2015 · first_quarter · Q1
Implementation of the Biologics Price Competition and Innovation Act (BPCIA); House 21st Century Cures Act Discussion Draft
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZYDUS PHARMACEUTICALS USA INC. via BROWN RUDNICK LLP
2014 · fourth_quarter · Q4
H.R. 5748 and S. 2948 - The Medicaid Generic Drug Price Fairness Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2014 · fourth_quarter · Q4
Implementation of P.L. 112-144 (FDA Safety and Innovation Act)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRIME THERAPEUTICS via BROWN RUDNICK LLP
2014 · fourth_quarter · Q4
HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014
Issues relating to generic pharmaceutical utilization and prescription drug abuse under the Medicare Part D prescription drug program. Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2014 · fourth_quarter · Q4
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2014 · fourth_quarter · Q4
Issues relating to diagnostic laboratory testing
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 - Medical Device Access and Innovation Protection Act; H.R. 523 - Protect Medical Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Federal policy relating to abuse deterrent drug development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015; H.R. 9 - The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to medical product cybersecurity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE